公开(公告)号：US20250011878A1

公开(公告)日：2025-01-09

申请号：US18711937

申请日：2022-11-22

Applicant: ITALFARMACO SPA

Inventor： Gianluca FOSSATI ,  Chiara RIPAMONTI ,  Christian STEINKÜHLER

IPC: C12Q1/6886

Abstract: The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as “gene expression signatures”, in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.

公开(公告)号：US20240207228A1

公开(公告)日：2024-06-27

申请号：US18555103

申请日：2022-04-19

Applicant: ITALFARMACO SPA

Inventor： Gianluca FOSSATI ,  Flavio LEONI ,  Pietro Samuele POZZI ,  Elisabetta GALBIATI ,  Christian STEINKÜHLER

IPC: A61K31/41 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/41 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/545

Abstract: The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.

公开(公告)号：US20190300496A1

公开(公告)日：2019-10-03

申请号：US16315576

申请日：2017-07-14

Applicant: ITALFARMACO SPA

Inventor： Andrea STEVENAZZI ,  Giovanni SANDRONE ,  Daniela MODENA ,  Samuele Pietro POZZI ,  Barbara VERGANI ,  Maria LATTANZIO ,  Paolo MASCAGNI ,  Christian STEINKÜHLER ,  Gianluca FOSSATI

IPC: C07D317/60 ,  C07C259/10 ,  C07D221/04 ,  C07D233/64 ,  C07D213/56 ,  C07D405/12 ,  C07D417/12 ,  C07D409/12 ,  A61P35/00

Abstract: The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.